ABCELLERA BIOLOGICS (8QQ) — Capital Reinvestment Ratio

Latest as of December 2022: 0.26x

ABCELLERA BIOLOGICS (8QQ) has a Capital Reinvestment Ratio of 0.26x as of December 2022, meaning it reinvests 0% of its operating cash flow (€277.36 Million) in capital expenditures (€72.66 Million). See ABCELLERA BIOLOGICS balance sheet independence to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.26x
Capex / Operating Cash Flow

Operating Cash Flow

€277.36 Million
EUR

Capital Expenditures

€72.66 Million
EUR

Data as of

Dec 2022
Most recent filing

ABCELLERA BIOLOGICS Capital Reinvestment Ratio (2021–2022)

This chart tracks ABCELLERA BIOLOGICS's Capital Reinvestment Ratio across 2 annual periods. Check ABCELLERA BIOLOGICS (8QQ) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for ABCELLERA BIOLOGICS (2021–2022)

Year-by-year Capital Reinvestment Ratio for ABCELLERA BIOLOGICS from 2021 to 2022. For live market cap and broader valuation context, see 8QQ stock market capitalisation.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2022 0.26x €277.36 Million €72.66 Million ▲ +9.6%
2021 0.24x €244.58 Million €58.45 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow